The Commercialization of Asia’s First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough
In 2023, CanSinoBIO’s meningococcal conjugate vaccine achieved revenue approximately RMB561.72 million, representing a year-on-year increase of approximately 266.39% compared to last year. The growth trend is evident. Among them, MCV4…